
Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target
Alnylam Pharmaceuticals (ALNY) Analyst Ratings
Bulls say
Alnylam Pharmaceuticals reported impressive total product revenue of $451 million for the fourth quarter, reflecting a 30% year-over-year increase, with full-year revenue rising by 33% to $1.65 billion. The company benefits from significant market potential, particularly in the ATTR-CM segment, where diagnosis rates have surged nearly tenfold since 2019, indicating a vast opportunity as approximately 80% of patients remain undiagnosed. Additionally, Alnylam's focus on innovative therapies in rare diseases and cardiovascular conditions, alongside strategic partnerships that enhance cash flow through upfront fees and potential royalties, supports a robust financial outlook.
Bears say
Alnylam Pharmaceuticals faces significant financial challenges, with substantial accumulated losses and an expected extended timeline before achieving profitability. The company’s reliance on future regulatory approvals for its therapeutic products presents a high-risk outlook, as any delays or failures could lead to downward revisions in financial projections and valuation metrics. Additionally, potential legal disputes related to intellectual property and increased competition may further hinder revenue growth and prolong the path to financial sustainability.
This aggregate rating is based on analysts' research of Alnylam Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Alnylam Pharmaceuticals (ALNY) Analyst Forecast & Price Prediction
Start investing in Alnylam Pharmaceuticals (ALNY)
Order type
Buy in
Order amount
Est. shares
0 shares